Phase III study of LIQ-861 in patients with pulmonary arterial hypertension
Phase of Trial: Phase III
Latest Information Update: 10 Jan 2018
At a glance
- Drugs LIQ-861 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Liquidia Technologies
- 10 Jan 2018 New trial record
- 03 Jan 2018 According to the Liquidia Technologies media release, based on the feedback from the FDA, data from this trial will support a potential U.S. regulatory approval of LIQ861.
- 03 Jan 2018 According to the Liquidia Technologies media release, company will enroll first patient in the next few weeks and topline data are expected in 2019.